ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said that 27 evaluable patients for the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for indolent lymphoma were enrolled during October, according to a Monday filing with the Hong Kong bourse.
The cancer drug is known to simultaneously bind CD47 and CD20 expressed on malignant B cells, leading to improved therapeutic outcomes, the filing noted.
The company's shares were down over 2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。